1. In Vivo
  2. >>Archive

NinePoint Medical Looks Deep For Barrett’s Esophagus

NinePoint Medical Inc. is looking to shed some insights on the mysteries of the esophagus. The venture-backed start-up launched NvisionVLE, an imaging system that can produce real-time images of the esophagus, enabling gastroenterologists to see where they need to cut when performing biopsies of tests of worrisome esophageal tissue including Barrett’s esophagus.

The esophagus remains somewhat of a mystery to gastroenterologists, particularly regarding the treatment of Barrett’s esophagus, a cellular change in the lining of the esophagus caused by chronic injury due to gastroesophageal reflux disease (GERD). Barrett’s is potentially a precursor to deadly esophageal cancer. But the progression from Barrett’s to cancer can be slow or even stalled. Physicians can’t be certain which patients will become the sickest, so protocol requires regular endoscopic screening with white-light probes and many biopsies taken from the esophageal wall to determine whether the disease is progressing.

Imaging companies and researchers have worked to lift the veil a bit. A report by Charles J. Lightdale, MD, a gastroenterologist with Columbia University and [New York-Presbyterian Hospital ],...

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Eleanor Malone

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Early Development Deals: Ipsen's Strategy For Biomarker-Driven Success

 
• By Eliza Slawther

Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.   

Shape Our Content: Take The Reader Survey

 
• By Eleanor Malone

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.

In Partnership with Cerba Research

Prioritizing Safety in CAR-T Therapy: Patient Monitoring with Cerba Research’s Testing Portfolio

The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.

More from In Vivo

US Health System Redesign Critical, NAM’s Medical Experts Warn Trump Government

 
• By Ashley Yeo

The whirlwind back-and-forth on US tariffs and Robert F. Kennedy jr.’s plans to deregulate health care have become all-preoccupying, but the National Academy of Medicine was first to set out President Trump’s health administration priorities.

Podcast: “Powerful Yet Unexplored”: Commit Biologics Tackles The Complement System

 
• By Anabel Costa-Ferreira

Mikkel Wandahl Pederson, CEO and chief scientific officer at Commit Biologics, discussed the company’s mission to harness the powerful complement system for the treatment of serious diseases.

ML-Assisted Genetic Risk Score Predicts GLP-1 Adverse Events

 
• By David Wild

Phenomix Science presented new data at Digestive Disease Week 2025 showing its machine learning-assisted genetic risk score can predict nausea and side effects from GLP-1 receptor agonists, aiding personalized obesity treatment.